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ABSTRAK 
 
Tindak Balas Ubat Berbahaya (Adverse Drug Reactions, ADR)  sering kali 
dikaitkan dengan kadar morbiditi dan mortaliti yang tinggi di serantau dunia. Dalam 
usaha menangani masalah ini, banyak negara menubuhkan sistem farmakovigilans 
kebangsaan di negara masing-masing. Kebanyakan sistem farmakovigilans yang ada 
kini bergantung sepenuhnya pada Sistem Laporan Spontan (Spontaneous Reporting 
System, SRS) ADR yang dikemukakan oleh profesional penjagaan kesihatan seperti 
doktor dan ahli farmasi.   
Dalam konteks ini, Malaysia menubuhkan sistem farmakovigilansnya pada tahun 
1987. Jawatankuasa Penasihat Tindak Balas Ubat Berbahaya Malaysia (Malaysian 
Adverse Drug Reaction Advisory Committee, MADRAC)  ditubuhkan di bawah 
naungan Pihak Berkuasa Kawalan Ubat (Drug Control Authority, DCA)  Malaysia untuk 
mendokumenkan laporan SRS yang diperoleh daripada profesional penjagaan kesihatan.  
Berdasarkan kebanyakan sistem laporan ADR secara spontan di seantero dunia, laporan 
ADR di Malaysia juga turut terkesan, terutamanya dalam kalangan farmasi komuniti. 
Data yang dikeluarkan oleh MADRAC menunjukkan bahawa kadar laporan yang 
dikemukakan oleh farmasi komuniti adalah rendah jika dibandingkan dengan negera 
lain. Tambahan pula, tiada kajian komprehensif  dijalankan di Malaysia untuk 
mengetahui alasan di sebalik permasalahan ini.  
 xvi
Tesis ini bermatlamat  untuk mengetahui pengetahuan, sikap dan persepsi / 
tanggapan yang ada pada  farmasi komuniti  berhubung dengan laporan ADR.  Di 
samping  itu, tesis ini juga memberi tumpuan terhadap halangan penglibatan yang 
mereka hadapi dalam aktiviti farmakovigilans dan pelaporan ADR.  Dalam usaha 
mencapai objektif penyelidikan, suatu metodologi gabungan yang menggunakan  
pendekatan kualitatif dan kuantitatif diaplikasikan.   
Untuk memahami alasan di sebalik permasalahan ini, sejumlah 16 farmasi 
komuniti telah  ditemu bual.  Hampir kesemua mereka  tidak begitu biasa dengan sistem 
farmakovigilans yang sedia ada serta mengatakan tidak tahu-menahu tentang utilitinya.  
Walaupun kesemua yang ditemu bual tidak mengemukakan sebarang laporan ADR, 
namun mereka menunjukkan sikap yang positif terhadap laporan ADR.    
Halangan tidak mengemukakan laporan ADR yang utama  adalah kerana mereka 
tidak biasa dengan sistem ADR, tiada borang laporan ADR, tidak tahu cara untuk 
membuat laporan,  ragu-ragu atau tidak yakin tentang kepentingan tindak balas serta 
tiada masa.  Selain menerima maklum balas daripada pihak berkuasa berkenaan, para 
peserta turut mencadangkan agar mereka diberi pendedahan yang meluas tentang   
sistem ini. 
Dalam usaha mengitlak dapatan kajian kualitatif awal, suatu tinjauan melalui pos 
dijalankan dengan semua farmasi komuniti (n = 470) di empat buah negeri di Utara 
Semenanjung Makaysia. Dengan kadar respons total 25.2 %, dapatan tinjauan mendapati 
bahawa majoriti responden (n = 75, 74%) tidak sedar atau tidak tahu-menahu tentang 
kewujudan sistem farmakovigilans yang sedia ada di negara ini. Walaupun lebih 
daripada separuh (n=65, 61.5%) responden menekankan  tentang kepentingan laporan  
 xvii
ADR, namun hanya  13 daripada mereka (12.9%) mengakui ada menghantar laporan 
ADR kepada  MADRAC. 
Halangan tidak mengemukakan laporan ADR yang biasa dihadapi oleh farmasi 
komuniti adalah tidak tahu di mana laporan perlu dibuat  (n = 75, 54.8%)  serta tidak 
pasti sama ada mudarat yang terjadi disebabkan ubat atau ADR (n = 46,44.2%). Oleh 
itu, fasa kajian ini cuba mengenal pasti jurang pengetahuan tentang laporan ADR dalam 
dikalangan farmasi komuniti yang akhirnya akan mengesahkan hasil kajian kualitatif.  
Berdasarkan hasil ini serta usaha memastikan bahawa pendidikan  jangka pendek 
mampu meningkatkan pengetahuan mereka, maka satu kajian intervensi pendidikan 
diolah dan dijalankan.   
Semua farmasi komuniti di negeri Pulau Pinang, Malaysia dipelawa untuk 
mengikuti seminar pendidikan sehari mengenai Farmakovigilans dan Laporan ADR.  
Seramai 42 farmasi komuniti turut mengambil bahagian dalam seminar ini.  Hasil  
perbandingan tentang pengetahuan sebelum dan selepas seminar, secara signifikannya 
menunjukkan adanya perbezaan yang berkaitan dengan  pengetahuan laporan ADR, dan 
penambahbaikan dalam skor min yang berkaitan dengan pengetahuan  farmakovigiland 
dan laporan ADR  (z = -5458, N= 42, p<0.001).  Hampir  sebahagian daripada peserta 
seminar (45%), begitu yakin bahawa mereka lebih berpengetahuan untuk mengesan serta 
melaporkan ADR  (z = -2.866, N=42, p = 0.004). 
Komponen awal penyelidikan semasa menonjolkan tentang kurangnya 
pengetahuan serta tanggapan yang salah di kalangan farmasi komuniti berhubung 
dengan laporan ADR.  Dalam memastikan bakal pengamal farmasi pada masa hadapan 
mendapat pendedahan yang secukupnya tentang laporan ADR dalam pengajian mereka 
di peringkat ijazah,  di samping menilai persepsi mereka  terhadap laporan ADR,  maka 
 xviii 
suatu kajian  telah diadakan yang melibatkan pelajar farmasi tahun akhir di semua 
universiti awan di Malaysia (n = 5). Dengan kadar respons total 84.0%, lebih kurang 
60% (n = 240) daripada responden menyatakan bahawa dalam kurikulum farmasi sedia 
ada, terdapat kursus tentang konsep farmakovigilans. Min skor pengetahuan 
farmakovigilans bagi pelajar farmasi tahun akhir adalah  6.91+1.36.  Terdapat perbezaan 
yang signifikan dalam min skor bagi pengetahuan konsep farmakovigilans berdasarkan 
universiti (F = 5.89; p <001). Majoriti  (n =343, 82.3%) responden merasakan perlunya 
dijelaskan perbezaan di antara kemudaratan yang disebabkan ubat dan ADR. 
Sebagai kesimpulan, tesis ini mengesahkan bahawa  terdapat jurang pengetahuan 
tentang farmakovigilans dan laporan ADR dalam kalangan farmasi komuniti serta bakal 
pengamal farmasi di Malaysia.  Faktor faktor utama yang dikenal pasti tentang 
kurangnya laporan ADR  menekankan betapa perlunya menentukan strategi yang 
bersesuaian untuk meningkatkan serta melestarikan laporan ADR di kalangan Pengamal 
Farmasi Komuniti di Malaysia.   
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BARRIERS TOWARDS PHARMACOVIGILANCE ACTIVITIES AMONG 
COMMUNITY PHARMACISTS AND FINAL YEAR PHARMACY STUDENTS 
IN MALAYSIA 
 
 
ABSTRACT 
 
Adverse Drug Reactions (ADRs) are associated with a high rate of morbidity and 
mortality worldwide. In order to overcome this problem, many countries around the 
world have established national pharmacovigilance systems. Most of the 
pharmacovigilance system nowadays depends largely on ADR Spontaneous Reporting 
System (SRS) by healthcare professional such as physicians and pharmacists.  
Within this context, Malaysia established its pharmacovigilance system in 1987. 
The Malaysian Adverse Drug Reaction Advisory Committee (MADRAC) was 
established under the umbrella of Drug Control Authority (DCA) for documenting SRS 
reports received from healthcare professionals. As with most of the spontaneous ADRs 
reporting system worldwide, the Malaysian SRS has also been affected by under-
reporting of ADRs especially by the community pharmacists.  
Data from MADRAC shows that the ADRs reporting rate by community 
pharmacists is low compared to their counterparts in the other countries. Furthermore, 
there are no comprehensive studies conducted to explore the reasons behind under 
reporting of ADRs among community pharmacists in Malaysia.  
This thesis aims to explore the knowledge, attitude and perception held by 
community pharmacists regarding ADR reporting. Additionally, this thesis will also 
focus on the perceived barrier which hinders the participation of community pharmacist 
 xx
in pharmacovigilance activities and ADRs reporting. In order to achieve the research 
objectives, a mixed methodology using qualitative and quantitative approaches was 
adopted.  
In order to have a deep understanding of the reasons behind the ADR under-
reporting among the community pharmacists, a total of sixteen community pharmacists 
were interviewed. Almost all the interviewed pharmacists were unfamiliar with the 
existing pharmacovigilance system and expressed unawareness about its utility. 
However, although all the interviewed pharmacists did not submit any ADR report, they 
showed a positive attitude towards ADR reporting. 
  The major barriers hindering community pharmacists from not reporting ADRs 
were unfamiliarity with the ADR reporting system, unavailability of ADR reporting 
forms, ignorance of how to report, doubt about the importance of the reaction and time 
constraint. Most of the participants not only recommended receiving of feedback from 
the regulatory authority but also emphasized rigorous educational outreach for the 
community pharmacists about the ADR reporting system. 
In order to generalize the initial qualitative study findings, a cross-sectional mail 
survey was undertaken with all community pharmacists (n = 470) practicing in 4 
northern states of Malaysia. With a total response rate of 25.2 %, the survey findings 
revealed that the majority of respondents (n = 75, 72.1 %)   were not aware of the 
existing pharmacovigilance system in the country.  Although more than half (n = 65, 
61.5%) of the respondents in this survey emphasized the importance of ADR reporting 
only 13 pharmacists (12.9%) claimed that they had submitted ADR reports to 
MADRAC. 
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Most common barriers reported by CPs for non-reporting were ignorance of 
where to report (n = 75, 54.8%) and uncertainty regarding the causal relationship 
between the drug and the suspected ADR (n = 46, 44.2%). Therefore, this phase of the 
study identified gaps in the knowledge regarding ADRs reporting among CPs which 
confirmed the findings of the qualitative study. Based on these findings, and in order to 
explore whether a short educational intervention will improve the current knowledge 
status among CPs on ADRs reporting, an educational intervention study was designed 
and conducted. 
All the CPs in the state of Penang, Malaysia were invited to participate in a one-day 
educational seminar on pharmacovigilance and ADR reporting. A total of 42 CPs 
participated in the educational seminar. A comparison of CPs knowledge before and 
immediately after the seminar showed significant differences in relation to knowledge of 
ADR reporting, and an improvement in the mean scores related to  knowledge of 
pharmacovigilance and adverse drug reactions reporting (z = -5458, N= 42, p<0.001). 
Upon completion of the education program, nearly half of the pharmacists (45%) 
believed that they were confident of their knowledge in detecting and performing ADR 
reporting (z = -2.866, N=42, p = 0.004). 
The initial components of the current research highlight the existence of 
knowledge deficit and misperception towards ADR reporting held by the CPs. In order 
to explore whether the future pharmacy practitioners have been exposed to an adequate 
knowledge on ADR reporting during their undergraduate study, as well as to evaluate 
their perception towards ADR reporting, a nationwide survey study was undertaken with 
all the final year pharmacy students enrolled in Malaysian public universities (n = 5). 
With a total response rate of 84.0%, about 60% (n = 240) of the respondents indicated 
 xxii
that they had received courses on pharmacovigilance concept during their current 
pharmacy curriculum. The mean knowledge score for pharmacovigilance of the final 
year pharmacy students was 6.91+1.36. There was a significant difference in mean score 
for pharmacovigilance concept knowledge according to universities (F = 5.89; p<001). 
The majority (n =343, 82.3%) of respondents felt that it was necessary to confirm the 
causal relationship between the drug and the ADR.  
In conclusion, this thesis confirmed the existence of knowledge gap in ADR 
reporting among Malaysian CPs and future pharmacy practitioners. The major identified 
factors for the low level of ADR reporting revealed in this research emphasized the 
urgent need to determine appropriate strategies to enhance and sustain ADRs reporting 
among CPs in Malaysia.  
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1 CHAPTER 1: GENERAL INTRODUCTION 
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1.1 Introduction 
The global interest in the monitoring of drug safety showed a remarkable increase in the 
last four decades especially after the thalidomide disaster in the sixties (Meyboom et al., 
1999). The thalidomide disaster opened up the issue of drug safety for the public and 
healthcare professionals alike and brought about an awareness of the importance of the 
systemic surveillance of drugs for Adverse Drug Reactions (ADRs)(Edwards & Olsson, 
2002). ADRs are defined as unintended consequences suspected to be related to the use 
of medicinal products, including herbal medicines (WHO, 1972). ADRs are often 
associated with high mortality and morbidity rates. They were believed to be the 4th to 
the 6th largest causes of death in the United States and were responsible for 0.3% to 
more than 10 % hospital admission in some countries and up to 20% of healthcare 
budget spent on drug complication and ADRs consequences (Lazarou et al., 1998; 
Rabbur Reza & Emmerton, 2005). ADRs have a major impact on the public health 
system and impose unnecessary and unreasonable economic burdens on the society 
although most of these ADRs are preventable (Ayani et al., 2000; Geisslinger et al., 
2000). 
The tragedy of the thalidomide disaster  in 1960s has led many countries to set 
their observational systems  for early detection of potential adverse drug reactions 
associated with pharmacotherapy (Meyboom et al., 1999). These systems became known 
as the pharmacovigilance systems. Pharmacovigilance has been defined by the World 
Health Organization (WHO) as “the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug related 
problems” (WHO, 2002a). In a few literature, it was defined as the process of 
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identifying and responding to safety issues related to marketed drugs under the practical 
conditions of clinical usage in large communities (Mann & Andrews, 2002; Rawlins, 
1995). Pharmacovigilance plays a crucial role in the study of medication safety 
(Herdeiro et al., 2006), and now it is regarded as the quality control system of the society 
(Arnaiz et al., 2001). The WHO program for monitoring of drug safety was established 
in 1968 as the pilot project with the participation of ten countries initially and as of May 
2010, 98 countries have joined the WHO Drug Monitoring Program, and in addition, 32 
associate members are awaiting compatibility between the national and international 
reporting formats. The  WHO Drug Monitoring Program database has grown from over 
600,000 to over 5 million reports (Uppsala Monitoring Centre, 2010). Malaysia was 
accepted as the 34th full member of the WHO Drug Monitoring Program in 1990. 
In fact, most of the pharmacovigilance systems around the world depend on spontaneous 
reporting systems to collect information about ADRs, where the reports are submitted on 
a voluntary basis from the (reporters) health care professionals and then the information 
is entered onto a data base which is assessed regularly for signal generating (Waller, 
2009b). Spontaneous reporting is considered the main mechanism in the 
pharmacovigilance system by which the ADRs are identified after the drug is released 
onto the market and it is the foundation of the WHO data base (Edwards & Olsson, 
2002). Unfortunately, the spontaneous ADR reporting system is affected by a number of 
weaknesses, the most noticeable of these being the phenomena of ADRs underreporting 
from healthcare professionals. The reasons behind underreporting were not well 
documented in the developing countries although it had been proposed early in the 
developed countries, there were numerous obstacles preventing health care professionals 
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from ADRs reporting as noted in the literature (Bateman et al., 1992; Inman, 1976; 
Vallano et al., 2005; Belton et al., 1995). 
In Malaysia, the Malaysian pharmacovigilance system is a spontaneous voluntary ADR 
reporting system. MADRAC is responsible for collecting ADR reports in the country. 
Physicians, dentists, pharmacists and recently patients are encouraged to report 
suspected ADRs to MADRAC. The Malaysian Spontaneous Reporting System like other 
SRSs around the world suffers from ADR under-reporting from healthcare providers and 
it was reported that the number of reports received by MADRAC was lower than the 
recommendations of The WHO Program for International Drug Monitoring. At the time 
of establishing this study, little information was known about the Malaysian community 
pharmacist’s knowledge, attitude and reporting behavior towards ADRs reporting 
system. 
Thus the aim of the present study was to gain insight into the knowledge, attitude 
and perception and to explore the reasons behind under-reporting of ADRs among of 
community pharmacists in Malaysia and also among future pharmacy practitioners.  
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1.2 Problem Statement 
One of the pivotal objectives of the spontaneous reporting of ADRs is to generate 
signals about new possible ADRs (Backstrom et al., 2004). SRS basically relies on the 
voluntary reporting of suspected ADRs from health-care professionals and in some 
countries from the patients themselves. Under-reporting of ADRs is the major problem 
that weakens the efficiency of the SRS. In the beginning, Inman et al. (1976) proposed 
the most common obstacles leading to the non-reporting of ADRs and then it has been 
reported in many different studies which were carried out amongst all health care 
professionals including the community pharmacists (Belton et al., 1995; Bateman et al., 
1992; Milstien et al., 1986; Inman, 1976). However, these factors vary from one country 
to another (Lopez-Gonzalez et al., 2009; Aziz et al., 2006). It was estimated that only 
around 6-10% of all ADRs are reported (Feely et al., 1990; Smith et al., 1996; Lumley et 
al., 1986). It was documented that knowledge has a major effect on the attitude and 
perception of the community pharmacists towards adverse drug reactions reporting. 
Previous studies indicated that educational interventions which aimed at improving the 
level of knowledge of ADR reporting among the community pharmacists had a positive 
effect (Granas et al., 2007). 
The literatures reported that community pharmacists can play a vital and supportive role 
in ADR reporting because they are considered as the first point of contact within the 
health care system and daily contact with patients makes them ideally placed to learn of 
possible ADRs (Van Grootheest et al., 2002b; Green et al., 1999). In some developed 
countries, it was estimated that the rate of ADR reporting among community 
pharmacists accounted for approximately 40% of the reports received by their 
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pharmacovigilance centers (Rabbur Reza & Emmerton, 2005). Although the community 
pharmacists had a positive attitude towards pharmacovigilance activities, they suffered 
from insufficient knowledge and virtually no experience with regard to the   reporting of 
ADRs (Sears & Generali, 2005). 
Malaysia, like other countries, depends on the spontaneous reporting system to collect 
information about ADRs. Malaysia became a member of the World Health Organization 
(WHO) program for international drug monitoring in 1990. The amount of ADR reports 
received by MADRAC (the body responsible for running the pharmacovigilance system) 
reached about 4826 reports in 2009 (MADRAC., 2009). However, this amount is 
considered low according to the WHO recommendation (Uppsala Monitoring Centre, 
2010). 
The Malaysian pharmacovigilance system, like most of the pharmacovigilance systems  
around the world, suffers from the under-reporting of ADRs by health care professionals 
(Aziz et al., 2006; Nichols et al., 2009). There is a lack of information about the reasons 
behind under reporting amongst health care professionals in general and community 
pharmacists in particular.  
This study is meant to gain insight into the knowledge, attitudes and perceptions held by 
Malaysian community pharmacists towards pharmacovigilance concept and adverse 
drug reactions process, as well as to investigate the barriers preventing community 
pharmacists from reporting the adverse drug reactions. 
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1.3 Rational of the Study 
 Malaysia, like many other countries, uses the pharmacovigilance system (PV) as 
the main way to collect information about ADR occurrences in both the hospital and 
community settings. In Malaysia, the pharmacovigilance system was established in 
1987. 
The effectiveness and success of any pharmacovigilance system depends highly 
on the participation of all health care professionals, including community pharmacists, 
and also relies upon the degree of co-operation and communication between these 
professions. 
As in most of the pharmacovigilance system around the world, Malaysian 
pharmacovigilance also suffers from the problem of ADR under-reporting (Haq, 2003). 
It has been documented that the knowledge, attitude, and perception of the community 
pharmacists have a major impact on the participation and contribution of this profession 
to the pharmacovigilance system (Sweis & Wong, 2000; Herdeiro et al., 2006; Bawazir, 
2006). 
The study of the knowledge, attitudes and perception of the community 
pharmacists towards the pharmacovigilance system and ADR reporting has already been 
researched in the developed countries but there is a lack of studies carried out and 
recorded in this country. 
Involvement of the community pharmacists in pharmacovigilance activities can 
improve the rate and the quality of the ADR reporting, as this profession has the 
competence and is suitably equipped to perform this task (Van Grootheest et al., 2002a; 
Herdeiro et al., 2008).  
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In Malaysia , although the  ADR reporting system has been in place for more 
than 30 years , very few studies have been conducted to gain insight into the barriers and 
factors which can facilitate the participation of the community pharmacists in the 
pharmacovigilance activities in  general and ADR reporting in particular. 
In a country like Malaysia, with multiethnic groups and a high rate of use of 
herbal and complementary medicine, community pharmacists can play a major role in 
detecting and reporting ADRs associated with the use of such products.  Based on the 
abovementioned justifications, it is obvious that there is an urgent need to conduct 
comprehensive studies to explore and evaluate the actual role and contributions made by 
the community pharmacists in the pharmacovigilance system activities. Due to the lack 
of information about the magnitude of ADRs under-reporting associated with the 
Malaysian pharmacovigilance system, it is necessary to carry out evaluation studies 
prior to any intervention aiming to improve the pharmacovigilance system. 
1.4 Aims  
This study in its entirety has two main parts; of which the first part (Qualitative method) 
is to explore and gather baseline information about the knowledge, attitude and 
perception of the Community Pharmacists towards Pharmacovigilance activities and 
ADR reporting. Furthermore, the study has been conducted to gain insight into the 
reasons and the perceived barriers for under-reporting amongst community pharmacists.  
The second part of the study (Quantitative methods) is mainly aimed at 
evaluating and assessing the knowledge, attitude and barriers towards ADR reporting 
amongst Malaysian community pharmacists and the final year pharmacy students (future 
pharmacy practitioners). Information about knowledge, attitude and barriers of the 
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community pharmacists have to be assessed and the needs associated with these factors 
have to be identified. This would provide valuable knowledge on the issue of ADR 
reporting and which can contribute to the development and evaluation of the 
pharmacovigilance system.  
The specific objectives of this study are:  
(1) To explore the knowledge, attitude and perception of the community pharmacists 
towards ADR reporting. 
(2) To evaluate the knowledge, attitude and perception towards ADR reporting 
system amongst community pharmacists. 
(3) To determine barriers faced by community pharmacists towards ADR reporting  
(4) To evaluate the impact of educational intervention on the knowledge and 
perception of the Malaysian community pharmacists towards pharmacovigilance 
and ADR reporting 
(5) To explore the factors that affect knowledge ,perception and practice towards 
performing ADR reporting  
(6) To assess the knowledge and perception of the final year pharmacy students 
towards pharmacovigilance and ADR reporting in some Malaysian public 
universities. 
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1.5 Significance of the Study 
1) This study has many important implications that can provide health care policy 
makers and planners with useful data to explore the current ADR reporting status 
among the community pharmacists. 
2) It will provide a base line data that can be used in the future evaluation or 
reconstruction plans for the current PV system. 
3) The study is the first of its kind in Malaysia that will evaluate the factors that 
could possibly affect ADRs reporting among healthcare professionals and 
community pharmacists in particular. 
4) It is also to evaluate the overall conditions of ADRs reporting by observing the 
present system in place so that suggestions to improve reporting amongst health 
professionals can be offered. 
5) The result of the study will help in improving the ADR reporting procedure by 
highlighting the drawbacks in the system. 
6) To provide to the policy makers and planners proper suggestions and a 
mechanisms that can be used to improve the ADRs reporting among community 
pharmacists in particular and the other health professionals in general. 
The study provides policy makers in MADRAC management with knowledge about the 
current situation of ADRs reporting and thus enabling them to discuss the suitable 
methodology to improve reporting process. 
The study will determine the actual intervention required in improving ADRs reporting 
through verifying the possible factors leading to underreporting. Information about 
ADRs reporting such as community pharmacists’ basic knowledge, attitude, perceptions 
 11
and barriers have to be assessed and the needs associated with these factors have to be 
identified. This will provide valuable data on the issues of pharmacovigilance and ADRs 
reporting can be utilized to improve and further evolutions of the pharmacovigilance 
system. 
The study highlights the awareness and attitudes of community pharmacists to ADR 
reporting guidelines and how their behavior could affect the rate of ADR reporting. 
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1.6 Thesis Overview 
This study is constructed in two parts; part A consolidates the qualitative section and 
part B consolidates the quantitative section. 
This thesis is composed of 7 chapters, including this chapter, and each chapter stands as 
a separate chapter. 
 
CHAPTER 1: 
This chapter is the introductory chapter and each topic of the study has been designated 
as a separate chapter. 
This chapter provides a general overview of the research problem statement. It also 
presents the general flow of the whole research project and organization of the thesis. 
 
CHAPTER 2: 
This chapter provides the background and overview of the subject area (ADRs 
definition, pharmacovigilance concept, impact of ADRs on public health care system 
and the role of the community pharmacists in ADR reporting). As a general literature 
review, the chapter highlights some of the major studies related to the research area. 
 
CHAPTER 3: 
This chapter represents the qualitative approach of the study, which details the 
methodology and findings from qualitative interviews with conveniently sampled 
community pharmacists in Penang Island, Malaysia.  
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Findings from interviews conducted with community pharmacists about their attitudes 
and perceptions of towards the Malaysian pharmacovigilance system activities and the 
ADRs reporting process were outlined. 
This chapter also discusses the issues related to the barriers which hinder the community 
pharmacists from reporting of adverse drug reactions and what logistic steps can be 
taken to overcome this problem. 
The conclusions made in this chapter serve as the basis for further research, which is 
described in the subsequent chapters (quantitative section). 
 
CHAPTER 4: 
This chapter describes the methodology and findings from quantitative survey involving 
all the community pharmacists practicing in the northern states of Malaysia. The survey 
aimed to assess their knowledge attitude, perceptions towards Malaysian 
pharmacovigilance system and ADRs reporting process. 
 
CHAPTER 5:  
The goal of this chapter is to study the effectiveness and the impact of an educational 
program on the knowledge of and perceptions of Malaysian community pharmacists 
towards pharmacovigilance activities and ADR reporting. 
 
 
 
 
 
 14
CHAPTER 6: 
Describes a comparative analysis of the knowledge and perceptions held by senior 
pharmacy students towards pharmacovigilance concept and ADRs reporting in 5 public 
universities in Malaysia  
 
CHAPTER7:  
By integrating the findings of each of the individual chapters, this chapter provides a 
conclusion about the study findings which is highlighted along with some further 
recommendations. 
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2 CHAPTER 2: LITERATURE REVIEW 
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2.1 Background  
2.1.1 Introduction  
The safe use of medicine is an important aspect that affects each and every member of 
society. Nowadays, reducing the incidence and consequences associated with ADRs is a 
crucial challenge in drug use. Despite the importance of medicine in the prevention and 
curing of diseases, its usage is usually associated with undesirable adverse reactions and 
sometimes fatal reactions (Edwards & Aronson, 2000). It has been reported that adverse 
drug reactions is associated with significant morbidity and  mortality with huge 
unnecessary economic burden (White et al., 1999). 
Pre-marketing studies conducted with the aim of studying effectiveness and 
safety of medicines often fail to detect rare and serious adverse reactions that can occur 
after the drug approval for use in human beings. The reasons for this are the purposive 
and the selective criteria which eliminate some population with specific conditions from 
being included in these studies. Moreover, most of these studies have a short period of 
follow up which eliminates the capability to detect the ADRs associated with the long 
term use of drugs (Stricker & Psaty, 2004; Psaty & Burke, 2006; Stephens, 1998b). 
It has been reported that there is an absence of a total figure of the incidence as 
well as the economic burden of ADRs. This absence is attributed to several factors 
including the difference in drug policy between the communities, methods used to detect 
ADR, and the terminology used to describe the adverse event. Previous studies indicated 
that the terminology had a significant impact on the rate and quality of ADRs reporting 
(Stephens, 1998a; Morimoto et al., 2004). A commentary by Ackroyed et al.(2006) 
concluded that the inconsistencies in the definitions of commonly used terms have an 
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adverse impact on the establishment of medication safety priorities which could distress 
the accuracy and the quality of event rates (Ackroyd-Stolarz et al., 2006). 
2.2 Definitions and Concept of ADR 
Despite the tremendous development in both the fields of pharmaceutical industry and 
pharmacotherapy, there is no drug that is absolutely safe. All drugs can produce 
biological or therapeutic effects with a high probability of producing undesirable or 
harmful effects. The greatest problem of these harmful effects is their capability to 
mimic a wide range of disease symptoms. This makes it difficult for detection and 
reporting of adverse reactions. These effects should be taken into account in the 
differential diagnosis of a wide range of medical conditions. 
 The huge costs associated with ADRs often adversely impact the heath care 
directions (Oberg, 1999). For these reasons, ADRs are considered as the negative 
consequences of  drug use (Gholami & Shalviri, 1999). Although there is a remarkable 
increase in concern about the issues related to drug safety among health care providers, 
health care institutions and the patients themselves, there is a great confusion and lack of 
knowledge regarding the terminology used to describe adverse drug reactions. It has 
been reported that one of the reasons behind the under estimation of the ADRs incidence 
rate is the difference in the terms used to describe ADRs (Stephens, 1998a; Waller, 
2009b). Lack of consistency in ADRs definitions makes systematic reviews of ADR data 
extremely difficult and also deters comparisons of ADR rates between trials (Loke & 
Derry, 2001; Freemantle et al., 1999). 
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2.2.1 Definition of Adverse Drug Reactions (ADRs) 
According to WHO’s definition which has been used more than 30 years, ADRs has 
been defined as “a response to a drug that is noxious and un-intended and occurs at 
doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for 
modification of physiological function”(WHO, 2002a). For this reason, adverse drug 
reactions are considered as adverse events with a causal link to a drug (Nebeker et al., 
2004). 
Grootheest et al. (2003) indicated that the WHO definition fails to define the 
term ADRs adequately (Van Grootheest et al., 2003b). Other critics have concluded the 
WHO definition as being vague because it includes all adverse reactions, despite how 
trivial it is (Edwards & Aronson, 2000). There have been other definitions raised to 
overcome this point and have focused on making the WHO definition much more 
precise by excluding the minor unwanted reactions. Laurence et al defined ADRs as “A 
harmful or significantly unpleasant effect caused by a drug at doses intended for 
therapeutic effect which warrants reduction of dose or withdrawal of the drug and /or 
predicts hazard from future administration” (Laurence & Carpenter, 1998).  
Edwards and Aronson (2000)  described the WHO definition for ADRs as having 
an unlimited scope, and proposed the following definition referring to ADRs: “an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the 
use of a medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment or alteration of the dosage regiment, or 
withdrawal of the product”  (Edwards & Aronson, 2000).  
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2.2.2 Adverse Drug Events (AE)/Adverse Drug Experience (ADE) 
An adverse drug event is defined as “Any untoward medical occurrence that may 
appear during treatment with a pharmaceutical product but which does not necessarily 
have a causal relationship with the treatment”(WHO, 2002a; Asscher et al., 1995). This 
implies an adverse drug reaction characterized by the suspicion of a causal relationship 
between the drug and the event, contrary to an adverse drug event (Farcas & Bojita, 
2009).  
However, an adverse drug experience has been defined as “ any adverse event 
associated with the use of a drug in humans, whether or not considered drug related 
including the following: an adverse event occurring in the course of the use of drug in 
professional practice, an adverse event occurring  from overdose whether accidental or 
intentional, an adverse event occurring from drug abuse, an adverse event occurring 
from drug withdrawal and any significant failure of expected pharmacological action”( 
Nelson,1988). In Malaysia, the Malaysian Adverse Drug Reaction Advisory Committee 
(MADRAC) define adverse drug experience as “any untoward medical occurrence that 
at any dose  results in death, leading to a life-threatening condition, requires inpatient 
hospitalization or prolongation of existing hospitalization, results in persistent or 
significant disability/incapacity, or is a congenital anomaly/birth defect”(MADRAC, 
2002).  It has been reported that adverse drug events and adverse drug experience used 
are synonymous (Ahmad et al., 1996). Furthermore, although the distinction between the 
adverse reactions and adverse event is vital, still these terms are widely misused (Waller, 
2009a). 
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2.3 Epidemiology of Adverse Drug Reactions  
Numerous studies have been carried out to study the incidence of ADRs in the 
hospital and community settings.  There was considerable variation in the incidence 
estimations of ADRs in these studies (Lazarou et al., 1998).  This variation was 
attributed to the difference in the methodologies used to identify ADRs as well as the 
difference in definitions applied to define an ADRs and the obvious development in the 
diagnostic methods (Beard & Lee, 2006; Tai-Yin et al., 2010). The Thalidomide tragedy 
the in 1960s triggered the interest in the monitoring of drug safety and stimulates the 
heightened interest in ADRs reporting (D'Arcy & Griffin, 1994).  
Many studies adopting both retrospective and prospective designs have been 
conducted aiming at estimating ADRs incidence in different settings. These  studies 
started in the 60s were the epidemiological data basis of ADRs that has been established 
(Beard & Lee, 2006). Despite  the proposed detailed analysis and criticism for the 
studies which has been published at that time (Karch & Lasagna, 1975),the large early 
studies concerned with the epidemiology of ADRs estimated that the incidence of ADRs 
ranged from 10 to 20 per cent in general practicing setting (Seidl et al., 1966; Smith et 
al., 1966; Ogilvie & Ruedy, 1967; Hurwitz, 1969). The  justification of the disparity in 
the rate figures was the difference in the methods used to detect and report ADRs and 
whether the researcher  depended on himself or relied on other people in identifying 
ADRs (Davies, 1985). 
 It  was reported that most studies only just give rough indicators about the 
incidence of ADRs due to the under-reporting phenomena associated with  ADRs 
spontaneous reporting systems  and also due to the poor communication, poor training 
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and education about drug safety among healthcare professionals (Davies, 1985; Lawton 
& Parker, 2002; Davies et al., 2007). 
A study conducted in  UK in the early 70s suggested that in general practice, 1 in 
40 consultations were for ADRs (Mulroy, 1973). Another  study conducted at the same 
period of time revealed that 25% of the practice population may have had an ADR 
(Martys, 1979). It was estimated that the incidence of ADRs in the community setting  
ranged from 2.6% to 41% of patients (Beard & Lee, 2006). 
In US, a telephone survey study carried out by Gandhi et al (2003) reported that 
25% of the study population experienced ADRs, with a total of 181 events. The  authors 
also concluded that the ADRs which occurred in the primary care setting were common 
and most of them were preventable (Gandhi et al., 2003). It was reported in anther 
cohort study that 421(27.6%) of 1523 of ADRs events were preventable (Gurwitz et al., 
2003)  
2.3.1 Adverse Drug Reactions as Cause for Hospital Admission 
Most of the studies conducted in the early 80s, reported that ADRs were 
responsible for large numbers of hospital admissions, with narrow ADRs reporting rates 
ranging from 2.9- 6.2 per cent. In addition, the rate of ADRs incidents among the 
patients admitted to the general medical wards were higher than that related to the total 
admission to hospitals (Black & Somers, 1984).  
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Findings from literature indicated that the hospitalization rates as a result of ADRs in the 
other developed countries did not differ from those reported in Britain and the United 
States.  For example, in  a prospective study conducted in France, it was reported that 
out of  3,137 admissions, 100 (3.19%) admissions  were due to ADRs (Pouyanne et al., 
2000), while the data from Hong Kong in the mid 90s reported that ADRs were 
responsible for 6.2% of overall hospital admissions (Chan & Critchley, 2006). Similarly, 
in Denmark, Hallas et al (2009) reported that drug related problems accounted for 10.8% 
of all hospital admissions among which 8.1% were ADRs (Hallas et al., 2009).The  
findings of a multi-center epidemiological study conducted in Italy between 1988 and 
1997 reported that ADRs were responsible for 3.4% hospital admissions (Onder et al., 
2008) while in the Netherlands, it was documented that ADRs were responsible for 
about 12% of hospital admissions (Mannesse et al., 2000). 
In the developing countries, there is paucity of data in the estimation of the rates of 
hospitals admissions due to ADRs. It may be due to the scarcity of studies aimed to 
estimate the incidence of ADRs or that most of these studies have been performed with a 
local nature in terms of objectives or the setting. However, data from India suggested 
that 0.7% of hospital admissions  were due to ADRs (Ramesh et al., 2003).  It  has been 
reported  in a cross-sectional study  conducted in Nigeria  that ADRs were responsible 
for about 0.5%  of the patient admissions to the Lagos State University Teaching 
Hospital (Oshikoya et al., 2007).  In a Zimbabwean study, Taylor et al (1988) suggested 
that  around 6% of the hospital admissions in Zimbabwe were attributed to ADRs 
(Taylor et al., 1988). 
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2.3.2 Incidence of Adverse Drug Reactions during Hospital Admission 
Previous studies suggested that the incidence of ADRs during hospital admission 
was about 5% with a range from1.5% to over 20% (Baker et al., 2004; Lazarou et al., 
1998). The Harvard medical practice study reported that about 3.7% of the admitted 
patients experienced ADR and the incidence of ADRs during hospitalization was 6% 
(Brennan et al., 2004; Leape et al., 1991). It was reported that the ADRs incidence rate 
during the hospital admission increased remarkably (Hajjar et al., 2007). A prospective 
study carried out in 1990-1993 suggested that the ADRs incidence rate had increased to 
2.43 per 100 admissions (Classen et al., 1997). Bates et al. (1995) reported that there 
were 6.5 ADRs per 100 admissions during the hospital stay (Bates et al., 1995). In US, a 
follow up study of more than 35, 000 patients admitted to the Salt Lake hospital between 
1998- 1990 showed that about 1.67% of the patients experienced ADRs (Classen et al., 
1997). 
2.3.3 Mortality Associated With Adverse Drug Reactions 
In the developed countries, ADRs remain as the one of the main causes of 
morbidity and mortality in the health care setting (Alexopoulou et al., 2008). Karch and 
Lasagna (1975) reported that  prevalence of fatal ADRs ranges between 0.1%-0.3% 
among admitted patients (Karch & Lasagna, 1975). In a meta-analysis undertaken by 
Lazarou et al (1998), it was reported that ADRs accounted for over 100,000 deaths, 
making ADRs one of the  leading causes of death in the United States (Lazarou et al., 
1998). Data from Scandinavian countries  reported that ADRs were the most common 
cause of death in general practice which accounted for about 3% - 5% of mortality in 
these countries (Juntti-Patinen & Neuvonen, 2002; Wester et al., 2008). 
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Pirmohamed et al (2004) in their prospective observational study suggested that the rate 
of incidence of fatal ADRs in UK was  about 0.15% (Pirmohamed et al., 2004). The  
extrapolation of the results of the previous study to the rest of UK indicated that ADRs-
induced hospital admissions would be responsible for 5,700 deaths every year (Beard & 
Lee, 2006). In the developing countries, there is a lack of data on mortality rates 
associated with ADRs. In addition, the WHO reported that data related to drug safety in 
the developing countries are limited and expect to find worse conditions than developed 
countries (WHO, 2002b). However, data from developed countries related to ADRs can-
not necessarily be generalized to developing countries, where the incidence, pattern, and 
severity of adverse reactions may differ markedly because of local environmental and 
genetic influences (Eliasson, 2006). The main reasons for the scarcity of data on 
mortality rates associated with ADRs in the developing countries are lack of resources, 
infrastructure and experience in the drug safety monitoring programs in the most of 
these countries (Pirmohamed et al., 2007). The problem is also attributed to the lack of 
legislation and proper drug regulations, including ADR reporting, a large number of 
substandard and counterfeit products circulating in their markets, a lack of independent 
information and the irrational use of drugs (WHO, 2002b). However, reports show that 
the mortality rate associated with ADRs in provincial hospitals in Saudi Arabia was 
found to be 3.8% from the overall deaths in the general practice (Ahmed, 2008). In 
India, it has been reported that the overall mortality rate due to ADRs was found to be 
1.8% (Ramesh et al., 2003). 
